Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rat...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.